Tissue penetration of meropenem in patients undergoing gynecologic surgery

Stanley Gall, David L. Hemsell, James A. McGregor, Mark G. Martens, Donald Pitkin, Sarah Allen

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The purpose of this study was to assess the tissue-penetrating ability of a new β-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at ~1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at ~1 hour was 13.3 μg/mL. The median fluid and tissue concentrations at ~1 hour were as follows: cervix, 8.5 μg/g; endometrium, 2.3 μg/g; fallopian tube, 1.9 μg/g; myometrium, 3.6 μg/g; ovary, 2.3 μg/g; and uterus, 2.3 μg/g. These tissue concentrations exceed the MICs of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.

Original languageEnglish (US)
Pages (from-to)S178-S180
JournalClinical Infectious Diseases
Issue numberSUPPL. 2
StatePublished - 1997

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Tissue penetration of meropenem in patients undergoing gynecologic surgery'. Together they form a unique fingerprint.

Cite this